This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.
The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Brian G. M. Durie, MD
National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Brian G.M. Durie, MD, has no relevant financial relationships to disclose.
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Shaji K. Kumar, MD: consultant/advisor (paid to institution): AbbVie, Amgen, Antengene, ArcellX, AstraZeneca, BeiGene, Bluebird Bio, Bristol-Myers Squibb, Janssen, K36, Loxo Oncology, Oncopeptides, Roche/Genentech, Sanofi; consultant/advisor: Secura Biotherapeutics, Takeda, Trillium; researcher (paid to institution): AbbVie, Allogene, Amgen, AstraZeneca, Bristol-Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, Novartis, Roche/Genentech, Regeneron, Takeda.
Professor of Medicine, Division of Hematology
Division of Experimental Pathology
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Comprehensive Cancer Center
Associate Medical Director, Mayo Clinic Center for Regenerative Biotherapeutics
Yi Lin, MD, PhD: consultant (paid to institution): A2 Biotherapeutics, Fosun, Gamida Cells, Iovance, Kite, Legend Biotech, NekTar Therapeutics, NexImmune, Novartis, Sorrento; data and safety monitoring board member: Pfizer; scientific advisory committee member: NexImmune, Chimeric Biotherapeutics; researcher (paid to institution): Bristol-Myers Squibb, BlueBird Bio, Boston Scientific, Kite/Gilead, Merck, Takeda.
Thomas G. Martin, MD
Associate Clinical Professor of Medicine
Associate Director, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California
Thomas G. Martin, MD: consultant: GlaxoSmithKline, Legend Biotech; researcher (paid to institution): Amgen, Janssen, Sanofi.
Philippe Moreau, MD
Professor of Clinical Hematology
University Hospital of Nantes
Philippe Moreau, MD: consultant/advisor/speaker: AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Sanofi, Takeda.
S. Vincent Rajkumar,
Edward W. and Betty Knight Scripps – Edward C. Rosenow, III
Professor of Medicine
Mayo Clinic Proceedings
S. Vincent Rajkumar, MD, has no relevant financial relationships to disclose.
Jesús F. San-Miguel, MD, PhD
Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Jesús F. San-Miguel, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Haemalogix, Janssen, Karyopharm, Merck Sharpe and Dohme, Novartis, Takeda, Regeneron, Roche, Sanofi, SecuraBio.
The planners and content peer reviewers from Clinical Care Options, LLC and the International Myeloma Foundation (IMF) do not have any relevant financial relationships to disclose.
Jim Mortimer: individual publicly traded stocks and stock options: AstraZeneca.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2023, through January 23, 2024:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.